[Long-term outcomes of homoharringtonine, cytarabine, daunorubicin or idarubicin (HAD/HAI) as induction chemotherapy in de novo acute myeloid leukemia]
[高三尖杉酯碱、阿糖胞苷、柔红霉素或伊达比星(HAD/HAI)作为新发急性髓系白血病诱导化疗的长期疗效]
期刊:Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
影响因子:
doi:10.3760/cma.j.issn.0253-2727.2016.02.002
Qin, Tiejun; Xu, Zefeng; Zhang, Yue; Lin, Yani; Ru, Kun; Fang, Liwei; Zhang, Hongli; Pan, Lijuan; Hu, Naibo; Qu, Shiqiang; Wang, Jingya; Xing, Ruixian; Xiao, Zhijian